Fereshteh Asgharzadeh

Dr. Fereshteh Asgharzadeh


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2017 in Cytokine
Verified
Journal Article
Closed access
RBRahimeh Bargi
Rahimeh Bargi
FAFereshteh Asgharzadeh
Fereshteh Asgharzadeh
FBFarimah Beheshti
Farimah Beheshti
MHMahmoud Hosseini
Mahmoud Hosseini
HSHamid Reza Sadeghnia
Hamid Reza Sadeghnia
MKMajid Khazaei
Majid Khazaei

1 May 2019 in The International Journal of Biochemistry & Cell Biology
Verified
Journal Article
Closed access
SPSeyed Mostafa Parizadeh
Seyed Mostafa Parizadeh
RJReza Jafarzadeh-Esfehani
Reza Jafarzadeh-Esfehani
SHSeyed Mahdi Hassanian
Seyed Mahdi Hassanian
SPSeyed Mohammad Reza Parizadeh
Seyed Mohammad Reza Parizadeh
SVSamaneh Vojdani
Samaneh Vojdani
AAAmir Avan
Amir Avan

27 November 2018 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
MBMaryam Moradi Binabaj
Maryam Moradi Binabaj
FAFereshteh Asgharzadeh
Fereshteh Asgharzadeh
AAAmir Avan
Amir Avan
FRFarzad Rahmani
Farzad Rahmani
ASAtena Soleimani
Atena Soleimani
SHSeyed Mahdi Hassanian
Seyed Mahdi Hassanian

24 June 2024 in Translational Oncology
Verified
Journal Article
Open access
FAFereshteh Asgharzadeh
Fereshteh Asgharzadeh
AMArghavan Memarzia
Arghavan Memarzia
VAVida Alikhani
Vida Alikhani
SBSima Beigoli
Sima Beigoli
MBMohammad Hossein Boskabady
Mohammad Hossein Boskabady
One of the main causes of death on the globe is cancer. Peroxisome-proliferator-activated receptors (PPARs) are nuclear hormone receptors, including PPARα, PPARδ and PPARγ, which are important in regulating cancer cell proliferation, survival, apoptosis, and tumor growth. Activation of PPARs by endogenous or synthetic compounds regulates tumor progression in various tissues. Although each PPAR isotype suppresses or promotes tumor development depending on the specific tissues or ligands, the mechanism is still unclear. PPARs are receiving interest as possible therapeutic targets for a number of disorders. Numerous clinical studies are being conducted on PPARs as possible therapeutic targets for cancer. Therefore, this review will focus on the existing and future uses of PPARs agonists and antagonists in treating malignancies. PubMed, Science Direct, and Scopus databases were searched regarding the effect of PPARs on various types of cancers until the end of May 2023. The results of the review articles showed the therapeutic influence of PPARs on a wide range of cancer on in vitro, in vivo and clinical studies. However, further experimental and clinical studies are needed to be conducted on the influence of PPARs on various cancers.

1 March 2021 in EXCLI Journal
Verified
Journal Article
Open access
MHMilad Hashemzehi
Milad Hashemzehi
FRFarzad Rahmani
Farzad Rahmani
MKMahdieh Khoshakhlagh
Mahdieh Khoshakhlagh
AAAmir Avan
Amir Avan
FAFereshteh Asgharzadeh
Fereshteh Asgharzadeh
SHSeyed Mahdi Hassanian
Seyed Mahdi Hassanian
The renin-angiotensin system (RAS) is up-regulated in patients with colorectal cancer (CRC) and is reported to be associated with poor prognosis and chemo-resistance. Here we explored the therapeutic potential of targeting RAS in CRC using Losartan, an angiotensin receptor blocker. An integrative-systems biology approach was used to explore a proteome-level dataset of a gene signature that is modulated by Losartan. The anti-proliferative activity of Losartan was evaluated using 2- and 3-dimensional cell culture models. A xenograft model of colon cancer was used to investigate tumor growth with Losartan alone and in combination with 5-FU followed by histological staining (Hematoxylin & Eosin and Masson trichrome staining), biochemical analyses, gene expression analyses by RT-PCR, western blot/IHC, or MMP Gelatin Zymography studies. Effects on cell cycle and cell death were assessed by flow cytometry. Losartan inhibited cell growth and suppressed cell cycle progression, causing an increase in CRC cells in the G1 phase. Losartan significantly reduced tumor growth and enhanced tumor cell necrosis. An impact on the inflammatory response, including up-regulation of pro-inflammatory cytokines and chemokines in CRC cells are potential mechanisms that could partially explain Losartan’s anti-proliferative effects. Moreover, metastasis and angiogenesis were reduced in Losartan-treated mice as observed by inhibited matrix metalloproteinase-2 and -9 activities and decreased tumor vasculature. These data demonstrate the therapeutic potential of combining chemotherapeutic regimens with Losartan to synergistically enhance its activity and target the renin-angiotensin system as a new approach in colorectal cancer treatment.

1 January 2017 in International Journal of Preventive Medicine
Verified
Journal Article
Open access
PDF file
AAAzam Abareshi
Azam Abareshi
FNFatemeh Norouzi
Fatemeh Norouzi
FAFereshteh Asgharzadeh
Fereshteh Asgharzadeh
FBFarimah Beheshti
Farimah Beheshti
MHMahmoud Hosseini
Mahmoud Hosseini
MKMajid Khazaei
Majid Khazaei
Background: Renin-angiotensin (Ang)-aldosterone system not only plays a key role in the regulation of circulatory homeostasis, but also it acts as a powerful pro-inflammatory mediator. The aim of this study was to evaluate the effect of captopril (Cap), a known Ang-converting enzyme inhibitor, on inflammation-induced cardiac fibrosis, and heart oxidative stress status in lipopolysaccharide (LPS)-induced inflammation in male rats. Methods: Fifty male rats were randomly divided into five groups control, LPS (1 mg/kg/day), LPS + Cap 10 mg/kg, LPS + Cap 50 mg/kg and LPS + Cap 100 mg/kg. After 2 weeks, blood samples were taken, and hearts were harvested for evaluation of tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6) and nitric oxide metabolite in serum and tissue hemogenate, histopathology (hematoxylin and eosin and Masson's trichrome) and oxidative stress status. Results: Serum IL-6 and TNF-α concentration were higher in LPS group compared to control and Cap reduced them, significantly. Heart TNF-α and IL-6 contents in LPS group were significantly higher than control (P < 0.05). The administration of Cap significantly decreased inflammatory markers level to control (P < 0.05). The higher levels of malondialdehyde and lower antioxidative markers (total thiol, superoxide dismutase, and catalase) in the heart were observed in LPS group and treatment by Cap improved them, dose-dependently. Histopathological study revealed cardiac fibrosis and more collagen content in LPS group which significantly improved by Cap treatment. Conclusions: Treatment by Cap reduced cardiac fibrosis possibly through improving oxidative stress status, and it can be considered to increase cardiac compliance in this condition.